louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02571699: Minimum Effective Volume of Lidocaine-Bupivacaine for Subgluteal Block
Official title: Minimum Effective Volume of Lidocaine-Bupivacaine for Ultrasound-Guided Subgluteal Sciatic Nerve Block
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Injuries to the Ankle and Foot
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor class: OTHER
First posted: 2015-10-08
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine the minimum effective volume of LA in 90 % of patients (MEV90) required for US-guided subgluteal sciatic nerve block.

Detailed description: The aim of this study is to determine the minimum effective volume of LA in 90 % of patients (MEV90) required for US-guided subgluteal sciatic nerve block.

Success rate is defined as a minimal composite score of 6 points (out of 8 points) at 30 minutes.

Eligibility criteria: Inclusion Criteria:

* age between 18 and 75 years
* American Society of Anesthesiologists classification 1-3
* body mass index between 20 and 35

Exclusion Criteria:

* adults who are unable to give their own consent
* pre-existing neuropathy (assessed by history and physical examination)
* coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets≤ 100, International Normalized Ratio≥ 1.4 or partial prothrombin time ≥ 50)
* renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100)
* hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100)
* allergy to LA
* pregnancy
* prior surgery in the subgluteal region
* chronic pain syndromes requiring opioid intake at home

Primary outcomes:
measure: success rate
timeFrame: 0-30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Montreal General Hospital
state: Quebec
Study officials:
affiliation: McGill University Health Centre/Research Institute of the McGill University Health Centre
name: De Tran, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00573599: Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department
Official title: Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Migraine Headache
Keywords: Migraine
Emergency
imitrex
prochlorperazine
Acute Migraine Headache in the Emergency Department
Lead sponsor: United States Naval Medical Center, Portsmouth
Sponsor class: FED
First posted: 2007-12-14
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: ED patients with acute migraine will be randomized to either prochlorperazine and Bendaryl OR imitrex. VAS for pain will be monitored, along with side effects. Primary outcome measure is improvement in pain scales between the groups.


Eligibility criteria: Inclusion Criteria:

* Acute migraine headache

Exclusion Criteria:

* Pregnant
* Hypertension
* Chest pain
* \< 18
* Allergy to any of the meds

Primary outcomes:
measure: Difference in pain measured by VAS
timeFrame: 80 min
Secondary outcomes:
measure: Degree of sedation, nausea, akathisia
timeFrame: 80 min
Other outcomes:
Locations:
city: Portsmouth
country: United States
facility: Naval Medical Center Portsmouth
state: Virginia
Study officials:
affiliation: US Navy
name: Frank Gutierrez, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04316299: Acute Kidney Injury in Patients Hospitalized With COVID-19
Official title: Acute Kidney Injury in Patients Hospitalized With COVID-19 in Wuhan, China: a Single-center Retrospective Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Acute Kidney Injury
Kidney Function
Lead sponsor: Nanfang Hospital, Southern Medical University
Sponsor class: OTHER
First posted: 2020-03-20
Enrollment: 287
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients admitted to Hankou Hospital in Wuhan with confirmed COVID-19 pneumonia from 5th Jan to 28th Feb.

Brief summary: The kidney may be affected in coronavirus-2019 disease (COVID-19). This study assessed the predictors and outcomes of acute kidney injury (AKI) among individuals with COVID-19.


Eligibility criteria: Inclusion Criteria:

* COVID-19 pneumonia patients diagnosed by WHO criteria

Exclusion Criteria:

* Patients who were younger than 18 years,
* Patients who had undergone renal replacement therapy (RRT) before admission,
* Patients whose entire stay lasted for less than 48 hours.

Primary outcomes:
measure: Rate of Acute Kidney Injury
timeFrame: From date of admission until the date of discharge or death from any cause, up to 60 days
Secondary outcomes:
measure: Rate of Death
timeFrame: From date of admission until the date of death from any cause, up to 60 days
measure: the length of hospital stay
timeFrame: From date of admission until the date of discharge or death from any cause, up to 60 days
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Hankou Hospital
state: Hubei
Study officials:
References:
Clinical trial NCT05850299: Interest of Performing Two 6-minute Walk Tests at the End of a Pulmonary Rehabilitation Program, in COPD Patients.
Official title: Interest of Performing Two 6-minute Walk Tests at the End of a Pulmonary Rehabilitation Program, in COPD Patients.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COPD
Keywords: pulmonary rehabilitation
exercise capacity
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2023-05-09
Enrollment: 176
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: COPD patients admitted for pulmonary rehabilitation program in pulmonary rehabilitation unit of CH des Pays de Morlaix (CHPM).

Brief summary: In pulmonary rehabilitation, the 6-Minute Walk Test (6MWT) is essential to assess the effects of the program on patients' health. Current guidelines don't recommend to perform two 6MWT at the end of pulmonary rehabilitation. However, a more recent study shows that two 6MWT should be performed at the end of the program to accurately and reliably assess patients' capacities.

The aim of this study is to compare the results of two tests performed at the end of the program by COPD patients to find out whether there is a benefit of performing two 6MWT at the end of pulmonary rehabilitation.


Eligibility criteria: Inclusion Criteria:

* Patient with stage 2 to 4 (A to D) COPD
* Admitted to pulmonary rehabilitation unit of CH des Pays de Morlaix (CHPM)
* To follow a pulmonary rehabilitation program (4 weeks)
* Patient aged 18 or over
* Patient able to formulate his non-opposition to participate in the study

Exclusion Criteria:

* Contraindication to perform the 6-Minute Walk Test
* Patient under legal protection
* Refusal of participation

Primary outcomes:
measure: 6 minute walk distance (6MWD)
timeFrame: Two hours
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: Chu Brest
Study officials:
affiliation: CH des pays de Morlaix
name: Marc BEAUMONT, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03693599: Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean
Official title: Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage in Obese Women Undergoing Elective Cesarean Delivery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Post Partum Hemorrhage
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-10-03
Enrollment: 1200
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: to compare effectiveness and tolerability of carbetocin versus syntometrine in prevention of Postpartum hemorrhage after cesarean section

Detailed description: A double-blind randomized study conducted on 1200 obese pregnant subjected randomly either to single 100 μg IV dose of carbetocin (600 women) or combination of 5 IU oxytocin and 0.5 mg ergometrine (600 women) after fetal extraction and before placental removal.

Prevention of postpartum haemorrhage (PPH) after cesarean section (CS) had been evaluated by measurement of drop of Hemoglobin and hematocrit, incidence of PPH and number of subjects needed additional oxytocic

Eligibility criteria: Inclusion Criteria:

* All participants are at 37 - 40 weeks of gestational age
* Noncomplicated pregnancy.
* obese women with BMI \> 30.

Exclusion Criteria:

* Participants with placenta previa,
* coagulopathy,
* preeclamptic
* known sensitivity to carbetocin,oxytocin or methergine were excluded

Primary outcomes:
measure: incidence of postpartum hemorrhage after CS
timeFrame: 24 hours
Secondary outcomes:
measure: side effects of drugs used
timeFrame: 24 hours
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: faculty of medicine Cairo university
Study officials:
affiliation: Cairo University
name: AHMED SAMY, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03745599: Evaluation of the Effects of Different Analgesics on Pericoronitis Pain and Quality of Life
Official title: Evaluation of the Effects of Different Analgesics on Pain and Health-related Quality of Life of Patients With Pericoronitis in the Short-term Period: A Randomized, Double-blind, Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Quality of Life
Keywords: Pericoronitis
Analgesics
Non steroid anti-inflammatory drugs
Benzydamine
Quality of life
Lead sponsor: Near East University, Turkey
Sponsor class: OTHER
First posted: 2018-11-19
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Pericoronitis is a painful inflammatory condition which is well known for its negative impact on quality of life of those affected. The aim of this study was to test two hypotheses: (1) that topical application of Benzydamine is as effective as oral Diclofenac or Flurbiprofen in improving pain and quality of life of patients with pericoronitis and (2) that there would be no difference between the effects of the two oral NSAIDs on pain and quality of life of patients with pericoronitis


Eligibility criteria: Inclusion Criteria:

* Young adults aged 18 years or over
* Diagnosed with mild pericoronitis
* Having semi-impacted mandibular third molar
* Symptoms of pain and localized swelling

Exclusion Criteria:

* Smoking
* History of allergy to diclofenac, flurbiprofen, benzydamine or other NSAIDs
* Use of systemic antibiotics or analgesics within 3 days before admission
* The patients who had symptoms of severe pericoronitis such as fever higher than 101°F, dysphagia, trismus or facial swelling.

Primary outcomes:
measure: Oral Health-Related Quality of Life Scores Evaluated
timeFrame: Baseline
measure: Oral Health-Related Quality of Life Scores Evaluated
timeFrame: one week after drug prescribed
Secondary outcomes:
measure: Pain Scores Evaluated
timeFrame: Baseline
measure: Pain Scores Evaluated
timeFrame: one week after drug prescribed
Other outcomes:
measure: Oral Health Impact Profile (OHIP-14) Scores Evaluated
timeFrame: Baseline and one week after drug prescribed
Locations:
city: Mersin
country: Turkey
facility: Abdullah AlAlwani
Study officials:
affiliation: Near East University
name: Abdullah AlAlwani, DDS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00347399: Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
Official title: Effects of Intravitreal Injection of Bevacizumab in Combination With Verteporfin Photodynamic Therapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Age Related Macular Degeneration
Keywords: macular degeneration
antibodies
angiogenesis inhibitor
Lead sponsor: Asociación para Evitar la Ceguera en México
Sponsor class: OTHER
First posted: 2006-07-04
Enrollment: 25
Sex: ALL
Minimum age (years): 55
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.

Detailed description: The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined. The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD 4 days after photodynamic therapy with verteporfin

Eligibility criteria: Inclusion Criteria:

55 years old neovascular Age related acular degeneration subfoveolar neovascular membrane best corrected visual acuity better than 20/200 snellen (1.0 logMAR)

Exclusion Criteria:

* Previously treated eyes glaucoma diabetes mellitus uncontrolled hypertension coronary artery disease

Primary outcomes:
measure: Visual acuity improvement at 6 months
timeFrame: undefined
Secondary outcomes:
measure: Retinal thickness improvement at 6 months
timeFrame: undefined
Other outcomes:
Locations:
city: Mexico city
country: Mexico
facility: Hospital Luis Sanchez Bulnes
state: DF
Study officials:
affiliation: Asociación para Evitar la Ceguera en México
name: Hugo Quiroz-Mercado, MD
role: STUDY_DIRECTOR
affiliation: Asociación para Evitar la Ceguera en México
name: Jose Dalma Weizhaus, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5.
Clinical trial NCT04407299: COVID-19 Impact on Rheumatic Patients
Official title: Impact of COVID-19 Pandemic on Attitude, Behaviour and Mental Health of Patients With Rheumatic Diseases
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID
Keywords: Rheumatic patients
COVID-19
behaviour
Mental health
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Zagazig University
First posted: 2020-05-29
Enrollment: 360
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: a total of 360 participants were included in this study and divided into two groups: cases group composed of 180 patients with rheumatic diseases and control group composed of 180 healthy individuals

Brief summary: A study to assess the impact of coronavirus disease 2019 (COVID-19) pandemic on the attitude, behaviour and mental health of rheumatic patients and to compare them with healthy individuals.

Detailed description: To assess the impact of coronavirus disease 2019 (COVID19) pandemic on the attitude, behaviour and mental health of rheumatic patients and to compare them with healthy individual. This is cross-sectional survey, 360 participants were included and divided into cases group composed of 180 patients with rheumatic diseases and control group composed of 180 healthy people. Data were collected via a self-administered structured questionnaire (Google form) which was sent to participants via social networks and emails to different rheumatic patients and healthy individuals. Mental health was measured by the five-item Brief Symptom Rating Scale (BSRS-5).

Conclusion: Mental health should be addressed in the same manner we deal with the infectious disease itself, being of no less importance. It is essential for mental health professionals provide psychological support to vulnerable populations, including the infected and chronically ill patients and their families, individuals, communities and health care workers.

Eligibility criteria: Inclusion Criteria:

* adult patient with diagnosed rheumatic disease

Exclusion Criteria:

-

Primary outcomes:
measure: Score of five-item Brief Symptom Rating Scale (BSRS-5)
timeFrame: 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr Alainy Hospital
state: Non-US/Non-Canadian
Study officials:
affiliation: Cairo University
name: Mervat Eissa
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03204799: Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes
Official title: Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Type 2 Diabetes Mellitus
Dyslipidemias
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2017-07-02
Enrollment: 150
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: type 2 diabetes patients with oral hypoglycemic agent/insulin naive

Brief summary: Microbiota is important for immunology, hormonal and metabolic homeostasis in human and could influence on developing diabetes and obesity. Recent studies investigates microbiota by metagenomic sequencing, however, the composite of microbiota and its metabolic role has not been fully determined. Metagenomics and microbiome analysis could early diagnose metabolic disorders and suggest treatment options for metabolic diseases.

In this study, the investigators investigate the composite of microbiota and deduct basic information for treatment models using metagenomic sequencing.

Detailed description: 1. Cross-section study: normal/prediabetes/drug naïve type2 diabetes: compare microbiota using metagenomic sequencing among three groups.
2. Observational prospective study: metformin/sodium glucose co-transporter 2 (SGLT2) inhibitor/ezetimibe: compare microbiota using metagenomic sequencing before and after drug treatment.

Eligibility criteria: Inclusion Criteria:

* normal group: body mass index \[BMI\]\<23kg/m2, without diabetes mellitus history
* prediabetes group: fasting blood glucose ≥100 mg/dL and \<126 mg/dL or postprandial blood glucose ≥140 mg/dL and \<200 mg/dL
* type 2 diabetes according to ADA(American Diabetes Association) guideline (1) fasting blood glucose ≥126 mg/dL, (2) random blood glucose ≥200 mg/dL and with typical diabetes symptoms, (3) glycated hemoglobin A1c ≥6.5% and anti-hypoglycemic drug naive
* patients with type 2 diabetes, metformin monotherapy, SGLT2 inhibitor monotherapy
* patients with dyslipidemia, ezetimibe therapy

Exclusion Criteria:

* inflammatory bowel disease (Crohn's disease, ulcerative colitis)
* history of stomach, small intestine or colon resection operation
* on antibiotics therapy

Primary outcomes:
measure: Metagenomic profile change
timeFrame: 10 days (acute effect)
measure: Metagenomic profile change
timeFrame: 3 months (chronic effect)
Secondary outcomes:
measure: blood glucose change
timeFrame: 3 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center
Study officials:
References:
Clinical trial NCT01113099: Improving Adherence to Prescribing Guidelines for Cholesterol Lowering in Hospitalized Diabetic Patients
Official title: Assisted Detailing to Improve Guideline Adherence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Dyslipidemia
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2010-04-29
Enrollment: 247
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: We hypothesize that when compared to usual care a greater proportion of hospitalized diabetic patients who are candidates for cholesterol lowering will be discharged with a prescription for a statin if their physicians are contacted by a pharmacist to discuss treatment guidelines.


Eligibility criteria: Inclusion Criteria:

* Hospitalized patients with diabetes
* LDL \>= 100

Exclusion Criteria:

* Terminal illness
* Pregnancy
* Intolerance or contraindication to statin

Primary outcomes:
measure: Statin prescription at hospital discharge
timeFrame: Hospital discharge (avg = 3 days)
Secondary outcomes:
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: Barnes Jewish Hospital
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Thomas C Bailey, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: McKinnon PS, Seaton T, Noirot LA, Reichley RM, Heard KM, Shannon WD, Goldberg AC, Dunagan WC, Bailey TC. Improving adherence to dyslipidemia medication guidelines in hospitalized diabetic patients using a technology-assisted pharmacist intervention. AMIA Annu Symp Proc. 2008 Nov 6:868.
citation: Reichley R, McKinnon PS, Seaton T, Noirot L, Dunagan WC, Bailey TC. Adherence to dyslipidemia treatment guidelines in diabetic patients. AMIA Annu Symp Proc. 2006;2006:1071.
citation: Reichley R, Rachmiel E, Seaton T, Noirot L, Longyhore D, Dunagan WC, Bailey TC. Intervention to improve dyslipidemia screening in hospitalized diabetics. AMIA Annu Symp Proc. 2005;2005:1093.
citation: McKinnon PS, Reichley RM, Noirot LA, Dunagan WC, Bailey TC. Prospective validation of an algorithm to identify hospitalized diabetic patients using administrative data. AMIA Annu Symp Proc. 2006;2006:1029.